RT @CochraneEyes: New #Cochrane Review on #DMARDs (methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, and azathioprine) in the…
RT @CochraneNursing: 👀Which medications are safe and effective for treating non‐infectious intermediate, posterior & #panuveitis, an inflam…
RT @CochraneNursing: 👀Which medications are safe and effective for treating non‐infectious intermediate, posterior & #panuveitis, an inflam…
RT @CochraneNursing: 👀Which medications are safe and effective for treating non‐infectious intermediate, posterior & #panuveitis, an inflam…
👀Which medications are safe and effective for treating non‐infectious intermediate, posterior & #panuveitis, an inflammatory condition of the back part of the #eye? There are 11 RCTs included in this #CochraneReview 💁🏻https://t.co/9ceI4cjoiT @CochraneL
RT @CochraneEyes: New #Cochrane Review on #DMARDs (methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, and azathioprine) in the…
RT @CochraneEyes: New #Cochrane Review on #DMARDs (methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, and azathioprine) in the…
New #Cochrane Review on #DMARDs (methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, and azathioprine) in the treatment of non‐infectious intermediate, posterior, and #panuveitis (#NIIPPU) in adults. https://t.co/Wrmf49wZPl @RCOphth @Moorfields
SAREC FACULTY PUBS: Nov 2022 Non-biologic, steroid-sparing therapies for non-infectious intermediate, posterior, and panuveitis in adults. https://t.co/Af9NSZ0bBt